Advertisement
Home 2015

Archives

All packs of Auvi-Q injectors are being recalled in the United States as some may not deliver the correct dose of epinephrine

Sanofi Recalls Auvi-Q Injectors Used to Treat Anaphylaxis

0
Injectors may not deliver right amount of drug
The melanoma drug Yervoy (ipilimumab) can now be used to reduce the risk of the recurrence after surgery

FDA Approves Expanded Use for Melanoma Drug

0
Yervoy can now be used after surgery to reduce risk of skin cancer returning
Imlygic (talimogene laherparepvec) has been approved by the U.S. Food and Drug Administration to treat melanoma lesions of the skin and lymph nodes.

FDA Approves Imlygic for Melanoma

0
Injectable drug designed to rupture and kill cancer cells
Nearly 13 percent of American adults have tried electronic cigarettes at least once

CDC: E-Cigarette Use Highest Among 18- to 24-Year-Olds

0
Almost 4 percent of all adult Americans use them, new survey shows
Viekira Pak and Technivie appear linked to serious liver damage in patients with advanced liver disease

FDA Requires New Warning on Two Hepatitis C Drugs

0
Cautionary label will be added to Viekira Pak and Technivie, agency says
The U.S. Food and Drug Administration has approved Onivyde (irinotecan liposome injection) to be used in combination with fluorouracil and leucovorin in advanced pancreatic cancer.

FDA Approves Onivyde for Metastatic Pancreatic Cancer

0
To be used in combination with fluorouracil/leucovorin for advanced disease
The chemotherapy drug Yondelis (trabectedin) has been approved by the U.S. Food and Drug Administration to treat certain advanced or unresectable soft-tissue sarcomas.

FDA Approves Yondelis for Soft-Tissue Sarcoma

0
Drug sanctioned for liposarcoma or leiomyosarcoma
Coagadex (coagulation Factor X) has been approved by the U.S. Food and Drug Administration as the first coagulation factor replacement therapy for people with a rare blood disorder known as hereditary Factor X deficiency.

FDA Approves Coagadex for Rare Clotting Disorder

0
First coagulation therapy sanctioned for Factor X deficiency
Praxbind (idarucizumab) has been approved for use in patients who are taking the anticoagulant Pradaxa (dabigatran) when there is an urgent need to reverse Pradaxa's anticoagulant effects

FDA Approves Praxbind to Reverse Pradaxa’s Effect

0
Praxbind cleared for emergency use with Pradaxa when bleeding can't be controlled
Improved prescribing practices could help reduce opioid abuse and overdose deaths from those drugs

CDC: Prescribing Practices Key to Curbing Rx Abuse

0
Small number of doctors write most opioid prescriptions, study finds